Beijing startup lands AbbVie development deal for cancer therapies
Beijing’s Jacobio Pharma signed a collaboration deal with AbbVie to develop and commercialize its SHP2 inhibitors, a class of cancer therapy that can disrupt signaling pathways to slow down tumor growth.
SHP2 is a type of enzyme that is involved in cell signaling, cytokine production, and immune cell response. Genetic mutations in certain cancers leads to its amplification, which then promotes the development of tumors. Jacobio’s two lead candidates, dubbed JAB-3068 and JAB-3312, are designed to inhibit SHP2 activity.
Under the terms of the deal, AbbVie gains exclusive rights to the SHP2 portfolio and will cover the R&D costs of Jacobio’s early stage global clinical trials of JAB-3068 and JAB-3312. Upon completion of early stage trials, AbbVie will assume responsibilities of the drugs’ global development and commercialization. Jacobio can also exercise the option to exclusively develop and commercialize the SHP2 program in China, Hong Kong, and Macau.
BridgeBio Pharma’s subsidiary Navire Pharma is also developing an SHP2 inhibitor, called IACS-13909, while Novartis’ asset, TNO155, is currently in Phase 1 development.
SHP2 is a type of enzyme that is involved in cell signaling, cytokine production, and immune cell response. Genetic mutations in certain cancers leads to its amplification, which then promotes the development of tumors. Jacobio’s two lead candidates, dubbed JAB-3068 and JAB-3312, are designed to inhibit SHP2 activity.
Under the terms of the deal, AbbVie gains exclusive rights to the SHP2 portfolio and will cover the R&D costs of Jacobio’s early stage global clinical trials of JAB-3068 and JAB-3312. Upon completion of early stage trials, AbbVie will assume responsibilities of the drugs’ global development and commercialization. Jacobio can also exercise the option to exclusively develop and commercialize the SHP2 program in China, Hong Kong, and Macau.
BridgeBio Pharma’s subsidiary Navire Pharma is also developing an SHP2 inhibitor, called IACS-13909, while Novartis’ asset, TNO155, is currently in Phase 1 development.
No hay comentarios:
Publicar un comentario